Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PRKCA | P17252 | 4/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689676 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL30085025 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL5690133 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18072622 | 0.93 | PRKCA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL27167195 | 0.89 | ALDH1A1 (0.66) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL27167196 | 0.89 | ALDH1A1 (0.66) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL7755332 | 0.87 | PRKCA (0.59) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL7755337 | 0.87 | PRKCA (0.59) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL14452769 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL29040598 | 0.86 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1041976-B1 | POLYAMIDE OLIGOMERS | INEX PHARMACEUTICALS CORP (CA) | 2006-04-05 | — | — | EP | disclosed |
| US-6586559-B2 | Based on omega-amino (oligoethyleneglycol) alkanoic acid monomers; can be conjugated to lipids, nucleic acids, peptides, proteins, etc and used to form liposomes, virusomes, micelles, etc., optionally containing drugs | INEX PHARMACEUTICALS CORPORATION (CA) | 2003-07-01 | — | — | US | disclosed |
| US-20020026027-A1 | Polyamide oligomers | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2002-02-28 | — | — | US | disclosed |
| US-6320017-B1 | POLYLACTONES FROM OMEGA-AMINO(OLIGOETHYLENE OXIDE)ALKANOIC ACID MONOMERS; CAN BE CONJUGATED TO LIPIDS, NUCLEIC ACIDS, PEPTIDES, PROTEINS, ETC. | INEX PHARMACEUTICALS CORP. (CA) | 2001-11-20 | — | — | US | disclosed |
| EP-1041976-A1 | POLYAMIDE OLIGOMERS | Inex Pharmaceuticals Corp. (CA) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033493-A1 | POLYAMIDE OLIGOMERS | INEX PHARMACEUTICALS CORPORATION (CA) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026027-A1 | Polyamide oligomers | CLTA, PICALM, PUF60 | ALDH1A1 4835/4885LMNA 1198/4885PRKCA 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.